Oxidized LDL accumulation in experimental renal ischemia reperfusion injury model

Renal Failure

Volumn 29, Issue 4, 2007, Pages 409-415

  Kulah, Eyup ^a   Tascilar, Oge ^a   Acikgoz, Serefden ^a   Karadeniz, Guldeniz ^a   Tekin, Ishak Ozel ^a   Can, Murat ^a   Gun, Banu ^a   Barut, Figen ^a   Comert, Mustafa ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Ischemia reperfusion injury; Kidney; Ox LDL; PON 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD ANALYSIS; CONTROLLED STUDY; IMMUNOFLUORESCENCE TEST; KIDNEY ARTERY; KIDNEY ISCHEMIA; KIDNEY VEIN; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZATION; RAT; REPERFUSION INJURY; TISSUE SECTION;

ANIMALS; ARYLDIALKYLPHOSPHATASE; KIDNEY; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 34248550995     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701274975     Document Type: Article

References (31)

1. Liano F, Junco E, Pascual J, et al. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int. 1998;53:S16-S24.
2. Williams P, Lopez H, Britt D, Chan C, Ezrin A, Hottendorf R. Characterization of renal ischemia-reperfusion injury in rats. J Pharmacol Toxicol Methods. 1997;37:1-7.
3. Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol. 2004 Aug;15(8):1974-1982.
4. Parke AL, Liu PT, Parke DV Multiple organ dysfunction syndrome. Inflammopharmacology. 2003;11(1):87-95.
5. Troncoso P, Dominguez J, Martinez L, Zambrano N. Oxidative damage markers in a renal ischemic-reperfusion model: the protective effect of monoamine oxidase inhibition. Transplant Proc. 1995;27:1836-1838.
6. Horkko S, Binder CJ, Shaw PX, et al. Immunological responses to oxidized LDL. Free Radic Biol Med. 2000;28:1771-1779.
7. Shoenfeld Y, Sherer Y, George J, et al. Autoantibodies associated with atherosclerosis. Ann Med. 2000;32(Suppl. 1):37-40.
8. Lee HS, Jeong JY, Kim BC, Kim YS, Zhang YZ, Chung HK. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 1997;51:1151-1159.
9. Lee HS, Kim BC, Kim YS, Choi KH, Chung HK. Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells. Kidney Int. 1996;50:1582-1590.
10. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmac. 1998;31:329-336.
11. Paragh G, Seres I, Balogh Z, Varga Z, Karpati I, Matyus J, Ujhelyi L, Kakuk G. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron. 1998;80:166-170.
12. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330-335.
13. Comert M, Tekin IO, Acikgoz S, Ustundag Y, Ucan BH, Acun Z, Barut F, Sumbuloglu V. Experimental bile-duct ligation resulted in accumulation of oxidized low-density lipoproteins in BALB/c mice liver. J Gastroenterol Hepatol. 2004 Sep;19(9):1052-1057.
14. Sipahi EY, Tekin IO, Comert M, Barut F, Ustun H, Sipahi TH. Oxidized low-density lipoproteins accumulate in rat lung after experimental lung edema induced by alpha-naphthylthiourea (ANTU). Pharmacol Res. 2004;50(6):585-591.
15. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Disp. 1991;19:100-106.
16. Ha H, Endou H. Lipid peroxidation in isolated nephron segments Am J Physiol. 1992;263:F201-F207.
17. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372-1376.
18. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
19. Lee HS. Oxidized LDL, glomerular mesengial cell and collagen. Diabetes Res Clin Pract. 1999;45:117-122.
20. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
21. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649-1654.
22. Bosmans JL, Holvoet P, Dauwe SE, Ysebaert DK, Chapelle T, Jurgens A, Kovacic V, Van Marck EA, De Broe ME, Verpooten GA. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int. 2001 Jun;59(6):2346-2356.
23. Steinbrecher UP, Witztum JL, Parthasarathy S, Steinberg D. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis. 1987 Mar-Apr;7(2):135-143.
24. Davenport A, Hopton M, Bolton C. Measurement of malondialdehyde as a marker of oxygen free radical production during renal allograft transplantation and the effect on early graft function. Clin Transplant. 1995 Jun;9(3 Pt 1):171-175.
25. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation. 1994;57:211-217.
26. Fellström B, Larsson A. Pathogenesis and treatment perspectives of chronic graft rejection (CVR). Immunol Rev. 1993;134:83-98.
27. Ghanem H, van den Dorpel MA, Weimar W, Man in 'T Veld AJ, El-Kannishy MH, Jansen H. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int. 1996 Feb;49(2):488-493.
28. Deveraj S, Li DJ, Vazquez M, Jlalal I. Cyclosporin a does not increase the oxidative susceptibility of low density lipoprotein in vitro. Free Radical Biol Med. 1999;26(7/8):1064-1068.
29. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS. Cyclosporine increases the oxidizability of LDL in renal transplant recipients. Transplantation. 1994;58:663-669.
30. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol Med. 1999;26:892-904.
31. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M. Serum paraoxonase activity in familial hypercholesterolaemia and insulin dependent diabetes mellitus. Atherosclerosis. 1991;86:193-199.